Thorsten Graef

Thorsten Graef, M.D., Ph.D., joined as Chief Medical Officer on June 6, 2022. Previously, Dr. Graef served as Chief Medical Officer of Acepodia USA, a cell therapy company, from May 2021 through April 2022. Prior to Acepodia, Dr. Graef served as Vice President Early Oncology at AbbVie Inc., a biotechnology company, from March 2019 through April 2021. Prior to this position at AbbVie, Dr. Graef served as Head of Development of Pharmacyclics at Abbvie from December 2014 to February 2019, and as its Vice President of Clinical Research from October 2012 to December 2014. Earlier in his career, Dr. Graef was a Medical Director at Merck Sharpe & Dohme. Dr. Graef received M.D. and Ph.D. degrees from the University of Dusseldorf and was a Research Scholar in Structural Biology and Immunology at Stanford University School of Medicine.